Cargando…

High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy

Nimotuzumab (h-R3) is a humanized monoclonal antibody that is safe to use against epidermal growth factor receptor (EGFR). However, the available information is insufficient about the dose effect of monoclonal antibody against epidermal growth factor receptor for the treatment of esophageal squamous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chunyu, Fu, Xiaolong, Cai, Xuwei, Wu, Xianghua, Hu, Xichun, Fan, Min, Xiang, Jiaqing, Zhang, Yawei, Chen, Haiquan, Jiang, Guoliang, Zhao, Kuaile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699509/ https://www.ncbi.nlm.nih.gov/pubmed/26766917 http://dx.doi.org/10.2147/OTT.S89592

Ejemplares similares

Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma
por: Zhu, Zhengfei, et al.
Publicado: (2015)

Nomogram predicts survival benefit for non- metastatic esophageal cancer patients who underwent preoperative radiotherapy
por: Xie, Kenan, et al.
Publicado: (2018)

Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial
por: Liang, Jun, et al.
Publicado: (2013)

Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial
por: Yang, Xu, et al.
Publicado: (2021)

Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
por: González Fernández, Sandra, et al.
Publicado: (2022)

Genetic variant of ADH1C for predicting survival in esophageal squamous cell cancer patients who underwent postoperative radiotherapy
por: Xu, Xin, et al.
Publicado: (2022)

Conditional Survival of Patients Who Underwent Curative Resection for Esophageal Squamous Cell Carcinoma
por: Shin, Dong Wook, et al.
Publicado: (2022)

Radiotherapy for esophageal carcinoma: dose, response and survival
por: Luo, Yijun, et al.
Publicado: (2017)

Survival Outcomes and Predictors for Patients who Failed Chemoradiotherapy/Radiotherapy and Underwent Salvage Total Laryngectomy
por: Tsai, Ming-Hsien, et al.
Publicado: (2021)

Extensive clinical target volume in postoperative chemoradiotherapy for esophageal squamous cell carcinoma: a phase II clinical trial (ESO-Shanghai 9)
por: Ai, Dashan, et al.
Publicado: (2023)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

The Impact of Post-Mastectomy Radiotherapy on Survival Outcomes in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy
por: Lee, Janghee, et al.
Publicado: (2021)

Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma
por: Fei, Zhaodong, et al.
Publicado: (2020)

Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma
por: Zong, Jing-Feng, et al.
Publicado: (2021)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Prognostic variables for conditional survival in patients with esophageal squamous cell carcinoma who underwent minimally invasive surgery
por: Liang, Mingqiang, et al.
Publicado: (2022)

A nomogram based on phosphorylated AKT1 for predicting locoregional recurrence in patients with oesophageal squamous cell carcinoma
por: Yu, Weiwei, et al.
Publicado: (2017)

Study on chemotherapeutic sensitizing effect of nimotuzumab on different human esophageal squamous carcinoma cells
por: YANG, XIAOYU, et al.
Publicado: (2016)

Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer
por: Han, Xinghua, et al.
Publicado: (2017)

Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
por: Zhai, Rui-ping, et al.
Publicado: (2015)

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study
por: Kato, Ken, et al.
Publicado: (2018)

Comparison of perioperative and survival outcomes between sublobar resection and lobectomy of patients who underwent a second pulmonary resection
por: Yao, Xingxin, et al.
Publicado: (2021)

Nimotuzumab for COVID-19: case series
por: Abdo Cuza, Anselmo A, et al.
Publicado: (2021)

Evaluation of the value of ENI in radiotherapy for cervical and upper thoracic esophageal cancer: a retrospective analysis
por: Liu, Mina, et al.
Publicado: (2014)

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3
por: Zhao, Lei, et al.
Publicado: (2012)

Long term results of different radiotherapy techniques and fractions for esophageal squamous cell carcinoma
por: Deng, Jiaying, et al.
Publicado: (2020)

A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma
por: Li, H. M., et al.
Publicado: (2016)

Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma
por: Huang, Jianfeng, et al.
Publicado: (2017)

Methylation and expression of PTPN22 in esophageal squamous cell carcinoma
por: Deng, Jiaying, et al.
Publicado: (2016)

Pattern of tumor regression after neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma
por: Li, Bin, et al.
Publicado: (2023)

Effect of perioperative flurbiprofen axetil on long‐term survival of patients with esophageal carcinoma who underwent thoracoscopic esophagectomy: A retrospective study
por: Xie, Yanhu, et al.
Publicado: (2021)

The impact of thoracic duct resection on the long-term body composition of patients who underwent esophagectomy for esophageal cancer and survived without recurrence
por: Nishimura, Erica, et al.
Publicado: (2023)

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial
por: Yuan, Jing-Jing, et al.
Publicado: (2022)

Characteristics of the local recurrence pattern after curative resection and values in target region delineation in postoperative radiotherapy for lower thoracic esophageal squamous cell cancer
por: Liu, Jun, et al.
Publicado: (2017)

Profile of nimotuzumab in the treatment of high-grade glioma
por: Yang, Qun-ying, et al.
Publicado: (2015)

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
por: Crombet Ramos, Tania, et al.
Publicado: (2020)

Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy
por: Tanaka, Nobumichi, et al.
Publicado: (2013)

Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence
por: Subramanian, Sundaram, et al.
Publicado: (2019)

Post-therapy pathologic tumor volume predicts survival in gastric cancer patients who underwent neoadjuvant chemotherapy and gastrectomy
por: Tang, Xiaolong, et al.
Publicado: (2019)

Cetuximab or Nimotuzumab Versus Cisplatin Concurrent with Radiotherapy for Local-Regionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis
por: Liang, Zhong Guo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tf5331n37115pbtfp746qkfm14